Clinical Trial

PeRiopEratiVE SmokiNg CessaTion Trial

Study acronym: PREVENT
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated October 3, 2024 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
PREVENT is a multicentre, 2x2 factorial, randomized clinical trial that aims to determine the effect of cytisine versus placebo, as well as the effect of video messaging to support smoking cessation versus standard of care in perioperative patients. This trial aims to investigate the effects of cytisine and text messaging on 6-month continuous abstinence rates. PREVENT will also assess secondary outcomes at 30 days, 56 days and 6 months post-randomization: 7-day point prevalence abstinence, urge to smoke, time to first lapse, time to relapse, number of cigarettes smoking if still smoking, pulmonary complications, vascular complications, wound and infectious complications, stroke, time in hospital and acute hospital care.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2021-10-19; most recent amendment 2024-10-01.
Status change: Recruiting → Active, Not Recruiting 2024-10-01
Status change: Not Yet Recruiting → Recruiting 2024-01-17
Trial Details
NCT Number NCT05102123
Lead Sponsor Population Health Research Institute
Conditions Smoking (Tobacco) Addiction, Smoking Cessation
Enrollment 1,720 participants
Start Date 2024-01-15
Primary Completion 2026-07-01 (estimated)
Study Completion 2027-01-01 (estimated)
Updated on ClinicalTrials.gov 2024-10-03